All News
There is NO reason to withhold folate on day of MTX. Folic acid does not enter the cell via the RFC (folinic acid does). Therefore no evidence for competition. - Dr Joel Kremer @RheumNow #ACR18 🤔
Maeve Gamble MaeveGamble ( View Tweet)
Want to help reduce the wait time for people to get in to see a rheumatologist? Donate to the ACR Rheum Research Foundation! In addition to funding research to cure arthritis, @RheumResearch funds training programs like the one I trained at #Georgetown #ACR18 https://t.co/dfkrdLlaNE
Angus Worthing MD AngusWorthing ( View Tweet)
Breast feeding update in Rheumatic Patients:
TNF inhibitors as a class are compatible with breast feeding.
Prednisone doses < 20 mg/day OK for breast feeding. Patients on higher doses should delay breast feeding for four hours after administration #ACR18 #CleClinicRheum
Emily Littlejohn ELittlejohnDO ( View Tweet)
#ACR18
Short term relief during breastfeeding:
🌼 NSAIDs are compatible (ibuprofen preferred - short acting)
🌼 prednisone <20mg a day compatible
🌼 if using prednisone >20mg a day, then delay breastfeeding or discard milk for 4hr after administration
Kanika Monga, MD DrKanikaMonga ( View Tweet)
#ACR18 social media dinner with @rheumecraig @samwhittle @DrBhana @alhkim @jeffsparks @EBRheum @PhilipGardiner @BeckySueToo https://t.co/Kw0FejsnIE
Paul Sufka, MD psufka ( View Tweet)
Here's a view from the other direction from @DrBhana's phone. #ACR18 https://t.co/P6Ewkw3fxC
Paul Sufka, MD psufka ( View Tweet)
Thread: #ACR18 Round up with @RheumNow & Dr Kavanaugh. https://t.co/xqOs5LjwGi
Paul Sufka, MD psufka ( View Tweet)
Abstract 428. Pain reduction over 12 months using methotrexate for knee osteoarthritis. Good study: RCT, 12 months, statistically significant pain reduction in knee pain. (by comparison, MTX doesn't work for hand OA) #ACR18 https://t.co/lwdNNZvR0R
Paul Sufka, MD psufka ( View Tweet)
Abstract 221: DIP involvement in RA is about 2%. More women than men, and more in pts with higher disease activity. Might be poor prognostic indicator. #ACR18 https://t.co/YQR8kknRTl
Paul Sufka, MD psufka ( View Tweet)
Abstract 2220: gout flares and allopurinol use population study. Unfortunately, gout is *vastly* undertreated. Similar abstracts 1247, 1272 show that pharmacist driven gout care can work well #ACR18 https://t.co/09A85ehnf1
Paul Sufka, MD psufka ( View Tweet)
Abstract 404: using IL-17 inhibitor to treat supraspinatus tendinopathy in a rat model. This is a common shoulder tendinopathy, and IL-17 Involved in human cases. #ACR18 https://t.co/KwK6slNqA5
Paul Sufka, MD psufka ( View Tweet)
Abstract 2264: data to support use of methotrexate in granulomatous mastitis with good results. (Be aware of this condition - you *will* eventually see it) #ACR18 https://t.co/SsDdz21t5r
Paul Sufka, MD psufka ( View Tweet)
My article on @RheumNow: 'Negotiation Skills for Rheumatologists' https://t.co/NfsTXd9qLK #ACR18
Paul Sufka, MD psufka ( View Tweet)
Tocilizumab is an option in treating severe Thyroid eye disease #ACR18 https://t.co/I3iq8uOibh
Philip Gardiner PhilipGardiner ( View Tweet)
checkpoint inhibitor-related myositis has unique phenotype - myocarditis, myasthenia gravis-like symptoms abstract #2976 #ACR18 @RheumNow
Cassandra Calabrese CCalabreseDO ( View Tweet)
Take-home message from the basic science Year in Review is that TLR7 links together all this year’s novel findings in SLE pathogenesis. #ACR18 @RheumNow
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
Pascual Year in Review: Gut pathogen (E gallinarum) translocated to liver, drives murine SLE. Treatable with antibiotics or vaccination. #ACR18 @RheumNow https://t.co/C5dSvnSQZz
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
Merkel Year in Review: SPACE trial (JAMA 18) - opioids NOT superior to NSAIDs for function or pain in OA & back pain. #ACR18 @RheumNow https://t.co/jQgc1eR67E
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
Merkel Year in Review: Yui et al Mayo Clin Proc. - Arthrocentesis appears to be safe in patients using DOACs (NO bleeding in 1050 procedures).
Need to tell our ED colleagues.
#ACR18 @RheumNow
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
Merkel Year in Review: SCOT trial of ASCT in severe SSc. Superior outcomes with ASCT but important toxicity.
Key here is to choose the right patient and the right time. This will not be easy.
#ACR18 @RheumNow https://t.co/SnO3oMuCp8
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)